Morbidity in Klinefelter syndrome and the effect of testosterone treatment
- PMID: 32496001
- PMCID: PMC7413637
- DOI: 10.1002/ajmg.c.31798
Morbidity in Klinefelter syndrome and the effect of testosterone treatment
Abstract
Klinefelter syndrome (KS; 47,XXY) is the most common sex chromosome abnormality in males (150 per 100,000 males). The condition leads to hypergonadotropic hypogonadism and ever since the condition was described approximately 80 years ago, testosterone treatment has been the cornerstone in care for individuals with KS. However, KS is associated with an array of health-related and socioeconomic challenges and it is becoming progressively clear that proper care for boys and men with KS reaches far beyond simply supplementing with testosterone. There are no widely implemented guidelines for KS care, and studies investigating crucial aspects of testosterone treatment in individuals with KS, including both beneficial and potentially adverse effects, have only begun to emerge during the last decades. For this descriptive review, we present an overview of literature describing health-related outcomes of testosterone treatment in KS and outline the clinical applications of testosterone treatment in KS. Collectively, beneficial effects of testosterone treatment on overall health in KS are described with few apparent adverse effects. However, larger randomized studies in adult and pediatric patients are warranted to elucidate key aspects of treatment. We stress the implementation of centralized multidisciplinary clinics and the need for a dedicated international guideline to ensure optimal care of boys and men with KS.
Keywords: Klinefelter syndrome; hypogonadism; review article; testosterone treatment.
© 2020 Wiley Periodicals, Inc.
Conflict of interest statement
CONFLICT OF INTEREST
The authors declare no potential conflict of interest.
Figures
Similar articles
-
Anthropometry in Klinefelter syndrome--multifactorial influences due to CAG length, testosterone treatment and possibly intrauterine hypogonadism.J Clin Endocrinol Metab. 2015 Mar;100(3):E508-17. doi: 10.1210/jc.2014-2834. Epub 2014 Dec 16. J Clin Endocrinol Metab. 2015. PMID: 25514102
-
Long-term effect of testosterone replacement therapy on bone in hypogonadal men with Klinefelter Syndrome.Endocrine. 2018 Aug;61(2):327-335. doi: 10.1007/s12020-018-1604-6. Epub 2018 Apr 25. Endocrine. 2018. PMID: 29696556
-
Klinefelter Syndrome and medical treatment: hypogonadism and beyond.Hormones (Athens). 2015 Oct-Dec;14(4):531-48. doi: 10.14310/horm.2002.1622. Hormones (Athens). 2015. PMID: 26732150 Review.
-
Central hypogonadism in Klinefelter syndrome: report of two cases and review of the literature.J Endocrinol Invest. 2021 Mar;44(3):459-470. doi: 10.1007/s40618-020-01324-3. Epub 2020 Jun 14. J Endocrinol Invest. 2021. PMID: 32537678 Review.
-
The role of hypogonadism in Klinefelter syndrome.Asian J Androl. 2014 Mar-Apr;16(2):185-91. doi: 10.4103/1008-682X.122201. Asian J Androl. 2014. PMID: 24407186 Free PMC article. Review.
Cited by
-
Polymerase chain reaction-based assays facilitate the breeding and study of mouse models of Klinefelter syndrome.Asian J Androl. 2022 Jan-Feb;24(1):102-108. doi: 10.4103/aja.aja_38_21. Asian J Androl. 2022. PMID: 34100389 Free PMC article.
-
Sex chromosome aneuploidies in 2020-The state of care and research in the world.Am J Med Genet C Semin Med Genet. 2020 Jun;184(2):197-201. doi: 10.1002/ajmg.c.31808. Epub 2020 Jun 4. Am J Med Genet C Semin Med Genet. 2020. PMID: 32496026 Free PMC article. No abstract available.
-
Cohort profile: pathways to care among people with disorders of sex development (DSD).BMJ Open. 2022 Sep 21;12(9):e063409. doi: 10.1136/bmjopen-2022-063409. BMJ Open. 2022. PMID: 36130763 Free PMC article.
-
Pubertal induction and transition to adult sex hormone replacement in patients with congenital pituitary or gonadal reproductive hormone deficiency: an Endo-ERN clinical practice guideline.Eur J Endocrinol. 2022 Apr 21;186(6):G9-G49. doi: 10.1530/EJE-22-0073. Eur J Endocrinol. 2022. PMID: 35353710 Free PMC article.
-
Executive Dysfunction in Klinefelter Syndrome: Associations With Brain Activation and Testicular Failure.J Clin Endocrinol Metab. 2023 Dec 21;109(1):e88-e95. doi: 10.1210/clinem/dgad487. J Clin Endocrinol Metab. 2023. PMID: 37595261 Free PMC article.
References
-
- Abramsky L, & Chapple J (1997). 47,XXY (Klinefelter syndrome) and 47,XYY: estimated rates of and indication for postnatal diagnosis with implications for prenatal counselling. Prenatal Diagnosis, 17(4), 363–368. - PubMed
-
- Aksglaede L, Molgaard C, Skakkebaek NE, & Juul A (2008). Normal bone mineral content but unfavourable muscle/fat ratio in Klinefelter syndrome. Archives of Disease in Childhood, 93(1), 30–34. - PubMed
-
- Aksglaede L, Skakkebaek NE, Almstrup K, & Juul A (2011). Clinical and biological parameters in 166 boys, adolescents and adults with nonmosaic Klinefelter syndrome: A Copenhagen experience. Acta Paediatrica, 100(6), 793–806. - PubMed
-
- Artero A, Tarin JJ, & Cano A (2012). The adverse effects of estrogen and selective estrogen receptor modulators on hemostasis and thrombosis. Seminars in Thrombosis and Hemostasis, 38(8), 797–807. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical